User:Mr. Ibrahem/Lutetium (177Lu) oxodotreotide

Lutetium (177Lu) oxodotreotide, sold under the brand name Lutathera, is a medication used to treat gastroenteropancreatic neuroendocrine tumors (GEP-NET) which express somatostatin receptors. It improved time with stable disease from 9 months to 28 months. It is given by injection into a vein.

Common side effects include low lymphocytes, liver inflammation, high blood sugar, low potassium, and nausea. Other side effects may include low platelets, low red blood cells, and tiredness. It works by attaching to somatostatin receptors after which the radioactivity gives the cell.

Lutetium (177Lu) oxodotreotide was approved for medical use in Europe in 2017 and the United States in 2018. In the United States it costs about 54,000 USD per dose as of 2021.